Participated · Seed · Dec 2024

MoldCo operates the first clinician-led digital health service focused on making mold detox a routine component of preventative care. Through its telehealth platform, patients can obtain symptom screening, advanced biomarker lab tests starting at $99, virtual consultations with certified mold-toxicity specialists, and prescription therapies shipped directly to their homes. Typical treatment plans cost $150–$300 per month, positioning MoldCo as a far cheaper alternative to fragmented, in-person options that can run into the tens of thousands of dollars. The company is already offering lab testing in 46 states and clinical care in select states such as Florida, Massachusetts, Michigan, Ohio, and Texas, with nationwide coverage targeted for 2026. Near-term priorities include expanding its specialist network, enhancing proprietary care technology, scaling patient onboarding, and launching clinical research collaborations to raise physician and public awareness. Backed by leading physicians, researchers, and tech VCs, MoldCo has raised $11 million to date to accelerate these initiatives.

Participated · Series A · Feb 2023

Marker Learning offers remote learning and attention-disability evaluations and ongoing support, leveraging proprietary technology and a network of psychologists and educators. The company delivers comprehensive diagnostic reports within one month that can be submitted to schools or employers and used to secure test accommodations. Marker partners with school districts to act as an extension of special education teams and already reaches 1 million students through those partnerships. It aims to provide services at a fraction of the cost of traditional private evaluations—which can cost up to $14,000 and have waitlists beyond 24 months—to improve equity for students of color and low-income households. With Series A funding, Marker plans to expand into new geographies and broaden its platform to include tutoring, coaching, and other learning support services for individuals and schools. Co-founders Stefan Bauer and Emily Yudofsky, both diagnosed with dyslexia, lead the company. The company announced a $15 million Series A led by Andreessen Horowitz. Marker Learning operates a telepsychology platform that enables psychologists to virtually administer evidence-based learning disability assessments and deliver personalized action plans. The company partners with leading psychologists and learning-disability specialists and leverages proprietary technology to streamline the assessment process, reduce cost, and decrease turnaround time versus in-person services. Evaluations for dyslexia and other learning disabilities often cost over $10,000 and many cases go undiagnosed; Marker aims to make gold-standard assessments more accessible to schools and families. The platform was developed to address long waitlists and access issues that were exacerbated by the COVID-19 pandemic. Marker plans to use new funding to expand its team and accelerate geographic expansion across the United States. Co-founders Stefan Bauer and Emily Yudofsky started the company after their own diagnoses and bring experience from McKinsey, Google, and telemedicine entrepreneurship.

Participated · Seed · Jul 2022

Pogo operates an AI-enabled research platform and consumer app that verifies purchases through SKU-level transaction data to connect brands with actual buyers. Founded in 2020, the company reports more than 3 million opted-in U.S. users and visibility into 1 in 150 U.S. shopping trips, representing over $470 billion in transaction value. Its platform supports AI-moderated video interviews, quantitative surveys, and always-on behavioral triggers, delivering transcripts and insights within hours. Dozens of major consumer brands, consulting firms, and investment funds are reported users of the platform. Pogo’s app has been recognized by Newsweek as the top loyalty app in the United States for two consecutive years, and users earn money by sharing card transactions, receipts, app usage, and location visits. The company positions its verified data as a solution to survey fraud and unreliable respondents in traditional consumer research.

Participated · Series A · Jul 2022

Hang builds software that lets consumer brands replace conventional loyalty schemes with non-fungible tokens that act as dynamic membership passes. Each customer receives an NFT that can "level up" as they buy products, attend events or otherwise interact with the brand, unlocking progressively richer perks. Because the NFTs are on-chain and transferable, members can later sell their status, creating a liquid market that CEO Matt Smolin believes aligns incentives for both brands and consumers. Early adopters include Budweiser, Bleacher Report, Pinkberry and music-festival organizer Superfly, indicating traction across food, beverage, media and live-event verticals. Smolin argues that rising customer-acquisition costs are forcing brands to rethink loyalty, and that blockchain infrastructure offers a more flexible, engaging alternative to points-based systems. The company’s vision is to "shepherd in a new relationship between consumers and brands" by turning status tiers into tradable digital assets. No revenue or user figures were disclosed in the article, but the firm is positioning itself to capture budget from large consumer brands looking for next-generation retention tools.

Participated · Seed · Dec 2021

Nucleus Genomics provides clinical-grade whole-genome sequencing and comprehensive genetic risk assessments covering over 800 diseases. The platform combines genomics with lifestyle and wearable data to contextualize health information and deliver personalised recommendations. The company recently acquired Irish biotech Cambrean, an AI-based health platform that converts Oura ring and Apple Watch data into actionable health insights, and is rolling out features such as AI Doctor, pharmacogenomics, and family forecasting. Nucleus integrates with partners like Bionic Health and Legacy to expand consumer health offerings. Founded in the U.S. in 2021 by Kian Sadegh, the company emphasises making whole-genome sequencing widely accessible to prevent avoidable genetic tragedies. Financially, it has raised venture capital including a $14M Series A and prior investments from Seven Seven Six and Founders Fund. Nucleus Genomics offers a platform that calculates polygenic risk scores by analyzing users' uploaded genetic data from at‑home testing services or data from its own testing kits. The company lets customers order its genetic testing kit or upload results obtained elsewhere and provides information about genetic predisposition to certain conditions. Polygenic risk scores have faced scrutiny for European population bias, and the company says it aims to build models that work across populations. Nucleus emphasizes user data ownership and granular control over how and whether data is shared for research. The company has not yet launched mainstream and it is unclear how broader consumer access will look. Following the recent raise, Nucleus plans to grow its team and establish its own genetic testing infrastructure, including buying testing kits in bulk, and is considering international expansion. Nucleus Genomics provides a consumer-facing platform where users can upload genetic data from services like 23andMe or Ancestry, or order a testing kit, and receive polygenic risk scores via the company’s proprietary algorithms. The product focuses on presenting genetic and non-genetic information in a user-friendly format and aims to eventually calculate absolute disease risk. The company is still developing its polygenic risk score algorithms — described by the founder as the startup’s "secret sauce" — and plans to launch around January 2022. Nucleus says it will also enable users to opt in to share genetic data with drug companies in exchange for a potential dividend payment. The startup plans to grow its team from three to six or seven members as it readies the product. Financially, Nucleus announced a $3.5M seed raise to support algorithm development, product launch, and team expansion.